Deze pagina is automatisch vertaald en de nauwkeurigheid van de vertaling kan niet worden gegarandeerd. Raadpleeg de Engelse versie voor een brontekst.

Linking Postoperative Pain, GCF NLRP3 , and Treatment Success Following MTA Full Pulpotomy Vs Root Canal Treatment in Symptomatic Irreversible Pulpitis (NLRP3)

14 november 2026 bijgewerkt door: Bassant Yasser Shaker Ibrahim El-Saharty, Cairo University

Linking Postoperative Pain, GCF NLRP-3 Dynamics, and Treatment Success Following MTA Full Pulpotomy Versus Root Canal Treatment in Symptomatic Irreversible Pulpitis : A Randomized Clinical Trial

To compare MTA full pulpotomy with conventional non-surgical root canal treatment in mature mandibular permanent molars with symptomatic irreversible pulpitis. The comparison covers postoperative pain, analgesic consumption, change in GCF NLRP3 levels, and clinical and radiographic success. A further aim is to assess whether changes in GCF NLRP3 are related to pain and to success.

Studie Overzicht

Gedetailleerde beschrijving

Aim: To compare MTA full pulpotomy with conventional non-surgical root canal treatment in mature mandibular permanent molars with symptomatic irreversible pulpitis. The comparison covers postoperative pain, analgesic consumption, change in GCF NLRP3 levels, and clinical and radiographic success. A further aim is to assess whether changes in GCF NLRP3 are related to pain and to success.

Methods: This is a two-arm, parallel, assessor-blinded, randomized trial conducted at the Endodontic clinic, Faculty of Dentistry, Cairo University. Sixty patients with a periapical index score ≤ 2 will be randomized to receive either full pulpotomy with MTA or single-visit root canal treatment (n=30 per group). The primary outcome is postoperative pain at 24 hours on an 11-point Numerical Rating Scale. Secondary outcomes are:

pain at 6, 12, 48 and 72 hours and on day 7; number of ibuprofen 400 mg tablets taken over 7 days; GCF NLRP3 levels measured by ELISA preoperatively from tooth and healthy contralateral (internal control) and on day 7 from tooth; clinical and radiographic success at 6 and 12 months.

Analysis will follow the intention-to-treat principle, using the independent-samples t-test or Mann-Whitney U test, the chi-square or Fisher's exact test, and Spearman's rank correlation, with significance set at P ≤ 0.05.

Expected significance: The trial will show whether a simpler, pulp-preserving procedure offers pain and success outcomes comparable to root canal treatment, and whether GCF NLRP3 can serve as a chairside biomarker of healing.

Keywords: symptomatic irreversible pulpitis; full pulpotomy; mineral trioxide aggregate; root canal treatment; postoperative pain; NLRP3 inflammasome; gingival crevicular fluid

Studietype

Ingrijpend

Inschrijving (Geschat)

60

Fase

  • Niet toepasbaar

Contacten en locaties

In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.

Studie Locaties

    • Giza Governorate
      • Al Manyal, Giza Governorate, Egypte

Deelname Criteria

Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.

Geschiktheidscriteria

Leeftijden die in aanmerking komen voor studie

18 jaar tot 40 jaar (Volwassen)

Accepteert gezonde vrijwilligers

Ja

Geslachten die in aanmerking komen voor studie

Allemaal

Beschrijving

Inclusion Criteria:

  • Patients 18-40 years old.
  • Male or female
  • Mandibular molars with SIP: preoperative sharp, moderate or severe pain, with normal periapical radiographic appearance or slight widening(PAI ≤ 2)
  • Systemically healthy (ASA I) or controlled disease (ASA II)
  • Able to understand NRS and sign informed consent
  • Good oral hygiene, with no plaque or calculus, no bleeding on probing (BOP

Exclusion Criteria:

  • Medically compromised patients with significant systemic disorders (ASA III or IV)
  • History of intolerance to NSAIDs/ Use of ibuprofen in the last 12 hours
  • Two or more adjacent teeth requiring endodontic treatment
  • External or internal root resorption
  • Vertical root fracture
  • Periapical lesion
  • Controlled diabetes & smoking
  • Acute periapical abscess or acute exacerbation of a chronic abscess
  • Pregnancy
  • Long-term corticosteroid use
  • Mobility grade II or III
  • Previous root canal therapy
  • Non-restorability
  • TMJ problems, bruxism, clenching or traumatic occlusion
  • Inability to perceive given instructions
  • Antibiotic intake during the 10 days before treatment (may alter GCF inflammatory mediators)
  • Gingival bleeding (gingivitis), recession > 3 mm or pocketing at the GCF sampling sites of the study or contralateral tooth
  • Absent contralateral tooth, or one that is carious, deeply restored or endodontically treated (it is the GCF control)

Studie plan

Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.

Hoe is de studie opgezet?

Ontwerpdetails

  • Primair doel: Behandeling
  • Toewijzing: Gerandomiseerd
  • Interventioneel model: Parallelle opdracht
  • Masker: Enkel

Wapens en interventies

Deelnemersgroep / Arm
Interventie / Behandeling
Actieve vergelijker: Non-surgical root canal treatment

Canals explored with k-file #08 & #10 hand files; WL with EAL, confirmed radiographically.

Irrigation 3 mL of 2.5% NaOCl after every instrument, side-vented needle placed 2 mm from the apex to limit apical extrusion.

Instrumentation Single visit; crown-down with DOTA rotary files; EDTA gel in continuous brushing motion.

Shaping sequence

  • 17/.08 (19 mm)→orifice opener
  • 17/.03→ rotary glide path
  • 20/.04, #25/.04, #30/.04 and #35/.04; canals dried with sterile paper points.

Obturation MC radiograph within 0.5-1 mm of radiographic apex; CLC with ADseal resin sealer.

6 Coronal seal & baseline film Same GIC base & bonded composite as pulpotomy group; immediate postoperativeradiograph

After caries removal and de-roofing, the entire coronal pulp is amputated to the canal orifices with a sterile sharp excavator; chamber rinsed with 2.5% NaOCl.

Haemostasis Cotton pellet soaked in 2.5% NaOCl on radicular stumps with light pressure for 2 min, then inspect; repeat up to 10 min in total. Achieved when no fresh bleeding comes from any orifice. Time to haemostasis (min) recorded.

Pulp capping & restoration MTAputty , 2-3 mm over stumps and chamber floor, adapted with a moist pellet. After 10 min: glass-ionomer layer, then bonded resin composite in same visit If haemostasis is not achieved Bleeding not controlled within 10 min, or necrotic / non-bleeding radicular pulp → pulpectomy and RCT in the same visit (comparator protocol). Not withdrawn: recorded as a protocol deviation and counted as a pulpotomy failure (ITT); per-protocol sensitivity analysis excludes these cases.

Experimenteel: full pulpotomy with MTA

After caries removal and de-roofing, the entire coronal pulp is amputated to the canal orifices with a sterile sharp excavator; chamber rinsed with 2.5% NaOCl.

2 Haemostasis Cotton pellet soaked in 2.5% NaOCl on radicular stumps with light pressure for 2 min, then inspect; repeat up to 10 min in total. Achieved when no fresh bleeding comes from any orifice. Time to haemostasis (min) recorded.

3 Pulp capping & restoration MTAputty , 2-3 mm over stumps and chamber floor, adapted with a moist pellet. After 10 min: glass-ionomer layer, then bonded resin composite in same visit.

! If haemostasis is not achieved Bleeding not controlled within 10 min, or necrotic / non-bleeding radicular pulp → pulpectomy and RCT in the same visit (comparator protocol). Not withdrawn: recorded as a protocol deviation and counted as a pulpotomy failure (ITT); per-protocol sensitivity analysis excludes these cases.

Canals explored with k-file #08 & #10 hand files; WL with EAL, confirmed radiographically.

2 Irrigation 3 mL of 2.5% NaOCl after every instrument, side-vented needle placed 2 mm from the apex to limit apical extrusion.

3 Instrumentation Single visit; crown-down with DOTA rotary files; EDTA gel in continuous brushing motion.

4 Shaping sequence

  • 17/.08 (19 mm)→orifice opener
  • 17/.03→ rotary glide path
  • 20/.04, #25/.04, #30/.04 and #35/.04; canals dried with sterile paper points. 5 Obturation MC radiograph within 0.5-1 mm of radiographic apex; CLC with ADseal resin sealer.

Coronal seal & baseline film Same GIC base & bonded composite as pulpotomy group; immediate postoperativeradiograph

Andere namen:
  • conventional root canal treatment

Wat meet het onderzoek?

Primaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
postoperative pain after 24 hours
Tijdsspanne: 24 hours

using 11-point numeric rating scale (NRS) to score postoperative pain after 24 where 0 means no pain and 10 is worst imaginable pain

24 hours

Secundaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
postoperative pain after 6,12,48,72 and 7 days
Tijdsspanne: 6, 12, 48,72 hours and 7 days

using 11-point numeric rating scale (NRS) to score postoperative pain after 6, 12, 48,72 hours and 7 days where 0 means no pain and 10 is worst imaginable pain.

6, 12, 48,72 hours and 7 days
GCF levels of NLRP3
Tijdsspanne: preoperative and 7 days postoperative

using ELISA to detect levels of NLRP3 from gingival crevicular fluid

preoperative and 7 days postoperative
Clinical and radiographic success
Tijdsspanne: 6 months

Evaluating clinical success ( absence of pain, swelling , sinus tract/ fistula, and tooth is functional) and radiographic success ( absence of periapical radiolucency, internal/ external resorption)

6 months

Medewerkers en onderzoekers

Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.

Publicaties en nuttige links

De persoon die verantwoordelijk is voor het invoeren van informatie over het onderzoek stelt deze publicaties vrijwillig ter beschikking. Dit kan gaan over alles wat met het onderzoek te maken heeft.

Studie record data

Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.

Bestudeer belangrijke data

Studie start (Geschat)

1 december 2026

Primaire voltooiing (Geschat)

1 december 2027

Studie voltooiing (Geschat)

1 december 2028

Studieregistratiedata

Eerst ingediend

10 november 2026

Eerst ingediend dat voldeed aan de QC-criteria

14 november 2026

Eerst geplaatst (Werkelijk)

17 november 2026

Updates van studierecords

Laatste update geplaatst (Werkelijk)

17 november 2026

Laatste update ingediend die voldeed aan QC-criteria

14 november 2026

Laatst geverifieerd

1 november 2026

Meer informatie

Termen gerelateerd aan deze studie

Andere studie-ID-nummers

  • New ENDO 3.3.3-New ENDO 7.1.2

Plan Individuele Deelnemersgegevens (IPD)

Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?

ONBESLIST

Informatie over medicijnen en apparaten, studiedocumenten

Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel

Nee

Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct

Nee

Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .

Abonneren